CN114423499A - 与肿瘤激活的t细胞衔接子相关的组合物和方法 - Google Patents
与肿瘤激活的t细胞衔接子相关的组合物和方法 Download PDFInfo
- Publication number
- CN114423499A CN114423499A CN202080056153.1A CN202080056153A CN114423499A CN 114423499 A CN114423499 A CN 114423499A CN 202080056153 A CN202080056153 A CN 202080056153A CN 114423499 A CN114423499 A CN 114423499A
- Authority
- CN
- China
- Prior art keywords
- polypeptide
- polypeptide complex
- fab
- complex
- scfv
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
- A61K40/32—T-cell receptors [TCR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/50—Fusion polypeptide containing protease site
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962858254P | 2019-06-06 | 2019-06-06 | |
| US62/858,254 | 2019-06-06 | ||
| US202062978662P | 2020-02-19 | 2020-02-19 | |
| US62/978,662 | 2020-02-19 | ||
| PCT/US2020/036493 WO2020247871A2 (en) | 2019-06-06 | 2020-06-05 | Compositions and methods relating to tumor activated t cell engagers |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN114423499A true CN114423499A (zh) | 2022-04-29 |
Family
ID=73652312
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202080056153.1A Pending CN114423499A (zh) | 2019-06-06 | 2020-06-05 | 与肿瘤激活的t细胞衔接子相关的组合物和方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (3) | US20230220105A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3980131A4 (cg-RX-API-DMAC7.html) |
| JP (2) | JP2022535924A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20220052898A (cg-RX-API-DMAC7.html) |
| CN (1) | CN114423499A (cg-RX-API-DMAC7.html) |
| WO (2) | WO2020247867A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20200385440A1 (en) * | 2017-12-07 | 2020-12-10 | Janux Therapeutics, Inc. | Modified bispecific t cell receptors |
| JP7137696B2 (ja) | 2019-05-14 | 2022-09-14 | プロヴェンション・バイオ・インコーポレイテッド | 1型糖尿病を予防するための方法および組成物 |
| US20230220105A1 (en) * | 2019-06-06 | 2023-07-13 | Janux Therapeutics, Inc. | Tumor activated t cell engagers and methods of use thereof |
| KR20230092863A (ko) | 2020-06-11 | 2023-06-26 | 프로벤션 바이오, 인코포레이티드 | 제1형 당뇨병을 예방하기 위한 방법 및 조성물 |
| AU2021326469C1 (en) | 2020-08-11 | 2026-04-30 | Janux Therapeutics, Inc. | Cleavable linker compositions and methods |
| EP4259193A4 (en) | 2020-12-09 | 2025-01-15 | Janux Therapeutics, Inc. | Compositions and methods related to tumor activated antibodies targeting psma and effector cell antigens |
| CN114656562B (zh) | 2020-12-23 | 2023-11-03 | 北京天广实生物技术股份有限公司 | 结合人和猴cd3的抗体及其应用 |
| CN117616137A (zh) * | 2021-05-11 | 2024-02-27 | 佳努克斯治疗公司 | 靶向egfr和cd3的抗体及其用途 |
| AR125758A1 (es) * | 2021-05-12 | 2023-08-09 | Janux Therapeutics Inc | Composiciones y métodos relacionados con anticuerpos activados por tumores dirigidos a egfr y antígenos de células efectoras |
| MX2023013851A (es) | 2021-05-24 | 2023-12-08 | Provention Bio Inc | Metodos para el tratamiento de diabetes tipo 1. |
| EP4519326A4 (en) * | 2022-05-04 | 2026-05-06 | Janux Therapeutics Inc | TUMOR-ACTIVATED MULTISPECIFIC ANTIBODIES TO TARGET CD28 AND PD-L1 AND THEIR METHODS OF USE |
| AR129202A1 (es) * | 2022-05-04 | 2024-07-31 | Janux Therapeutics Inc | Anticuerpos activados por tumores que se dirigen a trop2 y usos de estos |
| CA3264784A1 (en) * | 2022-08-18 | 2024-02-22 | Immunocore Limited | MULTI-DOMAIN BONDING MOLECULES |
| CN121443645A (zh) * | 2023-05-03 | 2026-01-30 | 佳努克斯治疗公司 | 靶向cd3的肿瘤活化的抗体及其用途 |
| WO2025085862A2 (en) * | 2023-10-20 | 2025-04-24 | BioNTech SE | Multispecific t cell engagers compositions and methods of use thereof |
| CN122459332A (zh) * | 2023-10-20 | 2026-07-24 | 百欧恩泰欧洲股份公司 | 多特异性t细胞衔接体组合物及其使用方法 |
| GB2641580A (en) * | 2024-06-07 | 2025-12-10 | T Therapeutics Ltd | Tumour-transforming multispecific proteins |
| US20260226165A1 (en) * | 2024-12-17 | 2026-08-06 | Merck Sharp & Dohme Llc | Compositions and methods related to tumor activated molecules targeting nectin-4 and effector cell antigens |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008119567A2 (en) * | 2007-04-03 | 2008-10-09 | Micromet Ag | Cross-species-specific cd3-epsilon binding domain |
| WO2009068649A2 (en) * | 2007-11-30 | 2009-06-04 | Glaxo Group Limited | Antigen-binding constructs |
| US20160194399A1 (en) * | 2014-07-25 | 2016-07-07 | Cytomx Therapeutics, Inc. | Anti-cd3 antibodies, activatable anti-cd3 antibodies, multispecific anti-cd3 antibodies, multispecific activatable anti-cd3 antibodies, and methods of using the same |
| US20170369563A1 (en) * | 2016-05-20 | 2017-12-28 | Harpoon Therapeutics, Inc. | Single domain serum albumin binding protein |
| WO2019075405A1 (en) * | 2017-10-14 | 2019-04-18 | Cytomx Therapeutics, Inc. | ANTIBODIES, ACTIVISTIC ANTIBODIES, BISPECIFIC ANTIBODIES, AND BISPECIFICALLY ACTIVATED ANTIBODIES AND METHODS OF USE THEREOF |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20010031264A1 (en) * | 1996-01-25 | 2001-10-18 | Andrew Segal | Vaccine compositions and methods of modulating immune responses |
| JP2009540015A (ja) * | 2006-06-14 | 2009-11-19 | イムクローン・リミテッド・ライアビリティ・カンパニー | 抗egfr抗体の凍結乾燥製剤 |
| ES2716864T3 (es) * | 2007-06-06 | 2019-06-17 | Monsanto Technology Llc | Genes y usos para la mejora de plantas |
| GB0911566D0 (en) * | 2009-07-03 | 2009-08-12 | Immunocore Ltd | T cell receptors |
| WO2013041865A1 (en) * | 2011-09-22 | 2013-03-28 | Immunocore Limited | T cell receptors |
| PE20150605A1 (es) * | 2012-04-27 | 2015-05-28 | Cytomx Therapeutics Inc | Anticuerpos activables que se unen al receptor del factor de crecimiento epidermico |
| US9562110B2 (en) * | 2012-11-21 | 2017-02-07 | Wuhan Yzy Biopharma Co., Ltd. | Bispecific antibody |
| EP3628328B1 (en) * | 2014-01-31 | 2022-09-14 | Cytomx Therapeutics Inc. | Matriptase and u-plasminogen activator substrates and other cleavable moieties and methods of use thereof |
| IL300408B2 (en) * | 2015-01-20 | 2025-11-01 | Cytomx Therapeutics Inc | Matrix metalloprotease-cleavable and serine protease cleavable substrates and methods of use thereof |
| CN107709356A (zh) * | 2015-06-26 | 2018-02-16 | 南加利福尼亚大学 | 用于肿瘤特异性活化的掩蔽嵌合抗原受体t细胞 |
| ES3056995T3 (en) * | 2016-04-13 | 2026-02-25 | Vivia Biotech Sl | Ex vivo bite-activated t cells |
| MX2020012217A (es) * | 2018-05-14 | 2021-03-02 | Harpoon Therapeutics Inc | Porción de unión para activación condicional de moléculas de inmunoglobulina. |
| US20230220105A1 (en) * | 2019-06-06 | 2023-07-13 | Janux Therapeutics, Inc. | Tumor activated t cell engagers and methods of use thereof |
-
2020
- 2020-06-05 US US17/616,278 patent/US20230220105A1/en active Pending
- 2020-06-05 US US17/616,281 patent/US20230220109A1/en not_active Abandoned
- 2020-06-05 EP EP20819457.1A patent/EP3980131A4/en active Pending
- 2020-06-05 KR KR1020227000224A patent/KR20220052898A/ko active Pending
- 2020-06-05 CN CN202080056153.1A patent/CN114423499A/zh active Pending
- 2020-06-05 JP JP2021572583A patent/JP2022535924A/ja active Pending
- 2020-06-05 WO PCT/US2020/036489 patent/WO2020247867A2/en not_active Ceased
- 2020-06-05 WO PCT/US2020/036493 patent/WO2020247871A2/en not_active Ceased
-
2024
- 2024-07-26 US US18/785,900 patent/US20240376226A1/en not_active Abandoned
-
2025
- 2025-03-25 JP JP2025050785A patent/JP2025111446A/ja active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008119567A2 (en) * | 2007-04-03 | 2008-10-09 | Micromet Ag | Cross-species-specific cd3-epsilon binding domain |
| WO2009068649A2 (en) * | 2007-11-30 | 2009-06-04 | Glaxo Group Limited | Antigen-binding constructs |
| US20160194399A1 (en) * | 2014-07-25 | 2016-07-07 | Cytomx Therapeutics, Inc. | Anti-cd3 antibodies, activatable anti-cd3 antibodies, multispecific anti-cd3 antibodies, multispecific activatable anti-cd3 antibodies, and methods of using the same |
| US20170369563A1 (en) * | 2016-05-20 | 2017-12-28 | Harpoon Therapeutics, Inc. | Single domain serum albumin binding protein |
| WO2019075405A1 (en) * | 2017-10-14 | 2019-04-18 | Cytomx Therapeutics, Inc. | ANTIBODIES, ACTIVISTIC ANTIBODIES, BISPECIFIC ANTIBODIES, AND BISPECIFICALLY ACTIVATED ANTIBODIES AND METHODS OF USE THEREOF |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2025111446A (ja) | 2025-07-30 |
| WO2020247871A2 (en) | 2020-12-10 |
| EP3980131A2 (en) | 2022-04-13 |
| JP2022535924A (ja) | 2022-08-10 |
| KR20220052898A (ko) | 2022-04-28 |
| US20230220105A1 (en) | 2023-07-13 |
| US20230220109A1 (en) | 2023-07-13 |
| WO2020247871A3 (en) | 2021-01-28 |
| EP3980131A4 (en) | 2023-06-28 |
| US20240376226A1 (en) | 2024-11-14 |
| WO2020247867A3 (en) | 2021-02-04 |
| WO2020247867A2 (en) | 2020-12-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20240376226A1 (en) | Compositions and methods relating to tumor activated t cell engagers | |
| RU2563830C2 (ru) | Лечение остеоартрита и боли | |
| JP4970258B2 (ja) | ヒトインターロイキン−13に対する抗体およびそれらの使用 | |
| ES2543095T3 (es) | Agentes de unión a TLR3 | |
| EP3119806B1 (en) | Il-21 antibodies | |
| CN110914297B (zh) | 抗人白细胞介素2抗体及其用途 | |
| CN113366016B (zh) | 抗人白细胞介素5(il-5)单克隆抗体及其应用 | |
| CA2921260A1 (en) | Methods and compositions for prolonging elimination half-times of bioactive compounds | |
| US12377294B2 (en) | Anti-CD3 antibody folate bioconjugates and their uses | |
| CN110914302A (zh) | 可活化抗pdl1抗体及其使用方法 | |
| AU2008251943A1 (en) | Humaneered anti-factor B antibody | |
| JP2011225574A (ja) | Il−13結合剤 | |
| JP2019520818A (ja) | ヒトtgfb1、tgfb2及びtgfb3に結合するアンタゴニスト抗体、及び肺線維症を治療するためのそれらの使用 | |
| JP2007289187A5 (cg-RX-API-DMAC7.html) | ||
| WO2012170470A1 (en) | Compositions and methods for detection and treatment of cancer | |
| JP2021181487A (ja) | 新規な抗cd3抗体およびその使用 | |
| KR20210029709A (ko) | 항체-약물 컨쥬게이트 및 이의 암 치료 용도 | |
| JP2019537621A (ja) | 抗fstl3抗体およびその使用 | |
| WO2021190553A1 (zh) | 抗IL-1β的抗体、其药物组合物及其用途 | |
| CN119948057A (zh) | 双特异性抗C-Kit和抗CD203c抗原结合分子及其用途 | |
| KR20260035744A (ko) | 항-ne 항체 및 이를 포함하는 ne-과활성화 관련 질환의 예방 또는 치료용 약학적 조성물 | |
| HK40073760A (en) | Compositions and methods relating to tumor activated t cell engagers | |
| JP2025088767A (ja) | PSMA-STEAP1二重可変ドメイン免疫グロブリン(DVD-Ig)分子及び薬物コンジュゲート | |
| JP2026004267A (ja) | 抗cd79b抗体薬物コンジュゲート | |
| WO2025185619A1 (zh) | 抗体药物偶联物及其制备方法和用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 40073760 Country of ref document: HK |